Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARD trial of cabazitaxel versus alternate androgen receptor-targeted therapy in metastatic castration-resistant prostate cancer
NL-OMON47271Phase 4Active, not recruiting
- Sponsor
- Sanofi
- Start
- Aug 2016
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cabazitaxel, abiraterone and enzalutamide in prostate cancer (PCa) (2 arms), sponsored by Sanofi. Primary endpoint: Radiographic progression-free survival. Started Aug 2016; status: active, not recruiting.
02
Drugs
cabazitaxelabirateroneenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON47271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47271.